Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 67

1.

Enhanced anti-HIV functional activity associated with Gag-specific CD8 T-cell responses.

Julg B, Williams KL, Reddy S, Bishop K, Qi Y, Carrington M, Goulder PJ, Ndung'u T, Walker BD.

J Virol. 2010 Jun;84(11):5540-9. doi: 10.1128/JVI.02031-09. Epub 2010 Mar 24.

2.

Quantitative profiling of the full APOBEC3 mRNA repertoire in lymphocytes and tissues: implications for HIV-1 restriction.

Refsland EW, Stenglein MD, Shindo K, Albin JS, Brown WL, Harris RS.

Nucleic Acids Res. 2010 Jul;38(13):4274-84. doi: 10.1093/nar/gkq174. Epub 2010 Mar 22.

3.

Interferon-alpha produces significant decreases in HIV load.

Tavel JA, Huang CY, Shen J, Metcalf JA, Dewar R, Shah A, Vasudevachari MB, Follmann DA, Herpin B, Davey RT, Polis MA, Kovacs J, Masur H, Lane HC.

J Interferon Cytokine Res. 2010 Jul;30(7):461-4. doi: 10.1089/jir.2009.0090.

4.

Perforin and IL-2 upregulation define qualitative differences among highly functional virus-specific human CD8 T cells.

Makedonas G, Hutnick N, Haney D, Amick AC, Gardner J, Cosma G, Hersperger AR, Dolfi D, Wherry EJ, Ferrari G, Betts MR.

PLoS Pathog. 2010 Mar 5;6(3):e1000798. doi: 10.1371/journal.ppat.1000798.

5.

Host determinants of HIV-1 control in African Americans.

Pelak K, Goldstein DB, Walley NM, Fellay J, Ge D, Shianna KV, Gumbs C, Gao X, Maia JM, Cronin KD, Hussain SK, Carrington M, Michael NL, Weintrob AC; Infectious Disease Clinical Research Program HIV Working Group.; National Institute of Allergy and Infectious Diseases Center for HIV/AIDS Vaccine Immunology (CHAVI)..

J Infect Dis. 2010 Apr 15;201(8):1141-9. doi: 10.1086/651382. Erratum in: J Infect Dis. 2010 Aug 15;202(3):501.

6.

T-cell exhaustion: characteristics, causes and conversion.

Yi JS, Cox MA, Zajac AJ.

Immunology. 2010 Apr;129(4):474-81. doi: 10.1111/j.1365-2567.2010.03255.x. Epub 2010 Feb 23. Review.

7.

HIV controller CD4+ T cells respond to minimal amounts of Gag antigen due to high TCR avidity.

Vingert B, Perez-Patrigeon S, Jeannin P, Lambotte O, Boufassa F, Lemaître F, Kwok WW, Theodorou I, Delfraissy JF, Thèze J, Chakrabarti LA; ANRS EP36 HIV Controllers Study Group..

PLoS Pathog. 2010 Feb 26;6(2):e1000780. doi: 10.1371/journal.ppat.1000780.

8.

Genome-wide mRNA expression correlates of viral control in CD4+ T-cells from HIV-1-infected individuals.

Rotger M, Dang KK, Fellay J, Heinzen EL, Feng S, Descombes P, Shianna KV, Ge D, Günthard HF, Goldstein DB, Telenti A; Swiss HIV Cohort Study.; Center for HIV/AIDS Vaccine Immunology..

PLoS Pathog. 2010 Feb 26;6(2):e1000781. doi: 10.1371/journal.ppat.1000781.

9.

IFN-alpha-induced upregulation of CCR5 leads to expanded HIV tropism in vivo.

Stoddart CA, Keir ME, McCune JM.

PLoS Pathog. 2010 Feb 19;6(2):e1000766. doi: 10.1371/journal.ppat.1000766.

10.

Using 3 TLR ligands as a combination adjuvant induces qualitative changes in T cell responses needed for antiviral protection in mice.

Zhu Q, Egelston C, Gagnon S, Sui Y, Belyakov IM, Klinman DM, Berzofsky JA.

J Clin Invest. 2010 Feb;120(2):607-16. doi: 10.1172/JCI39293. Epub 2010 Jan 25.

11.

Common genetic variation and the control of HIV-1 in humans.

Fellay J, Ge D, Shianna KV, Colombo S, Ledergerber B, Cirulli ET, Urban TJ, Zhang K, Gumbs CE, Smith JP, Castagna A, Cozzi-Lepri A, De Luca A, Easterbrook P, Günthard HF, Mallal S, Mussini C, Dalmau J, Martinez-Picado J, Miro JM, Obel N, Wolinsky SM, Martinson JJ, Detels R, Margolick JB, Jacobson LP, Descombes P, Antonarakis SE, Beckmann JS, O'Brien SJ, Letvin NL, McMichael AJ, Haynes BF, Carrington M, Feng S, Telenti A, Goldstein DB; NIAID Center for HIV/AIDS Vaccine Immunology (CHAVI)..

PLoS Genet. 2009 Dec;5(12):e1000791. doi: 10.1371/journal.pgen.1000791. Epub 2009 Dec 24.

12.

Immune and virological benefits of 10 years of permanent viral control with antiretroviral therapy.

Guihot A, Tubiana R, Breton G, Marcelin AG, Samri A, Assoumou L, Goncalves E, Bricaire F, Costagliola D, Calvez V, Rouzioux C, Autran B, Katlama C, Carcelain G; ALT-ANRS CO-15 study group.; DECAMUNE study group..

AIDS. 2010 Feb 20;24(4):614-7. doi: 10.1097/QAD.0b013e32833556f3.

PMID:
19952710
13.

Dynamics and consequences of IL-21 production in HIV-infected individuals: a longitudinal and cross-sectional study.

Iannello A, Boulassel MR, Samarani S, Debbeche O, Tremblay C, Toma E, Routy JP, Ahmad A.

J Immunol. 2010 Jan 1;184(1):114-26. doi: 10.4049/jimmunol.0901967. Epub 2009 Nov 30.

14.

Effective simian immunodeficiency virus-specific CD8+ T cells lack an easily detectable, shared characteristic.

Vojnov L, Reed JS, Weisgrau KL, Rakasz EG, Loffredo JT, Piaskowski SM, Sacha JB, Kolar HL, Wilson NA, Johnson RP, Watkins DI.

J Virol. 2010 Jan;84(2):753-64. doi: 10.1128/JVI.01596-09. Epub 2009 Nov 4.

15.

Induction of type I interferon by RNA viruses: cellular receptors and their substrates.

Baum A, García-Sastre A.

Amino Acids. 2010 May;38(5):1283-99. doi: 10.1007/s00726-009-0374-0. Epub 2009 Nov 1. Review. Erratum in: Amino Acids. 2011 Apr;40(4):1263.

16.

Clinical outcomes of elite controllers, viremic controllers, and long-term nonprogressors in the US Department of Defense HIV natural history study.

Okulicz JF, Marconi VC, Landrum ML, Wegner S, Weintrob A, Ganesan A, Hale B, Crum-Cianflone N, Delmar J, Barthel V, Quinnan G, Agan BK, Dolan MJ; Infectious Disease Clinical Research Program (IDCRP) HIV Working Group..

J Infect Dis. 2009 Dec 1;200(11):1714-23. doi: 10.1086/646609.

PMID:
19852669
17.

Effector mechanisms in HIV-1 infected elite controllers: highly active immune responses?

Blankson JN.

Antiviral Res. 2010 Jan;85(1):295-302. doi: 10.1016/j.antiviral.2009.08.007. Epub 2009 Sep 4. Review.

18.

Defective human immunodeficiency virus-specific CD8+ T-cell polyfunctionality, proliferation, and cytotoxicity are not restored by antiretroviral therapy.

Migueles SA, Weeks KA, Nou E, Berkley AM, Rood JE, Osborne CM, Hallahan CW, Cogliano-Shutta NA, Metcalf JA, McLaughlin M, Kwan R, Mican JM, Davey RT Jr, Connors M.

J Virol. 2009 Nov;83(22):11876-89. doi: 10.1128/JVI.01153-09. Epub 2009 Sep 2.

19.

Partial inhibition of human immunodeficiency virus replication by type I interferons: impact of cell-to-cell viral transfer.

Vendrame D, Sourisseau M, Perrin V, Schwartz O, Mammano F.

J Virol. 2009 Oct;83(20):10527-37. doi: 10.1128/JVI.01235-09. Epub 2009 Aug 12.

20.

APOBEC3B deletion and risk of HIV-1 acquisition.

An P, Johnson R, Phair J, Kirk GD, Yu XF, Donfield S, Buchbinder S, Goedert JJ, Winkler CA.

J Infect Dis. 2009 Oct 1;200(7):1054-8. doi: 10.1086/605644.

Supplemental Content

Support Center